期刊文献+

肠易激综合征血循环microRNA的表达谱 被引量:4

Expression prof ile of circulating microRNAs in patients with irritable bowel syndrome
下载PDF
导出
摘要 目的:探讨腹泻型肠易激综合征(irritable bowel syndrome,IBS)、便秘型IBS和正常人体血循环中微小核糖核酸(microRNA,miRNA)的表达差异,寻找潜在的IBS异常miRNA表达谱.方法:按罗马Ⅲ标准临床诊断IBS,根据临床特点分为腹泻型IBS和便秘型IBS.分别选取3份腹泻型IBS、3份便秘型IBS和3份正常人的混合血清标本,miRNA表达芯片检测血清标本中miRNA的表达水平,并进行聚类分析.结果:miRNA表达芯片分析发现,与正常人相比较,腹泻型IBS血循环中2种miRNA表达下调,2种miRNA表达上调;便秘型IBS血循环中4种miRNA表达下调,59种miRNA表达上调;只在腹泻型IBS血循环中差异表达的miRNA有1种,只在便秘型IBS血循环中差异表达的miRNA有60种,miR-23b在两种IBS血循环中都表达显著下调,hcmv-miR-US5-2、hsv2-miR-H11都表达显著上调.与腹泻型IBS相比较,便秘型IBS血循环中1种miRNA表达下降,26种miRNA表达上调.结论:IBS血循环具有异常的miRNA表达谱,提示血循环miRNA可作为IBS潜在的诊断标志. AIM: To investigate the differential expression of circulating microRNAs (miRNAs) between diarrhea-predominant irritable bowel syndrome (D-IBS)/constipation-predominant irritable bowel syndrome (C-IBS) and normal controls to profile abnormally expressed circulating miRNAs in IBS patients. METHODS: Patients were diagnosed with D-IBS or C-IBS based on the Rome III criteria. MiRNA microarray was performed to detect mixed se-rum samples of either three patients with D-IBS, three patients with C-IBS, or three normal controis. After miRNA profiling, clustering analysis was conducted.RESULTS: Compared to normal controls, there were two miRNAs down-regulated and two miRNAs up-regulated in the D-IBS group, and four miRNAs down-regulated and 59 miRNAs up-regulated in the C-IBS group. There was only one miRNA that was expressed differentially in D-IBS patients and 60 miRNAs in C-IBS patients. MiR-23b* was down-regulated and HCMV-miR- US5-2 and hsv2-miR-Hll up-regulated in both types of IBS. Compared to D-IBS patients, one miRNA was down-regulated and 26 miRNAs up-regulated in C-IBS patients. CONCLUSION: Abnormal expression profile of circulating miRNAs in IBS patients may provide new biomarkers for diagnosis of this disease.
出处 《世界华人消化杂志》 CAS 北大核心 2013年第5期392-396,共5页 World Chinese Journal of Digestology
基金 国家自然科学基金资助项目 No.81060037~~
关键词 肠易激综合征 MIRNA 表达谱 Irritable bowel syndrome MiRNA Expression profile
  • 相关文献

参考文献16

  • 1肠易激综合征诊断和治疗的共识意见(2007,长沙)[J].中华消化杂志,2008,28(1):38-40. 被引量:431
  • 2Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-1390.
  • 3Kapeller J, Houghton LA, M?nnikes H, Walstab J, M?ller D, B?nisch H, Burwinkel B, Autschbach F, Funke B, Lasitschka F, Gassler N, Fischer C, Whorwell PJ, Atkinson W, Fell C, Büchner KJ, Schmidtmann M, van der Voort I, Wisser AS, Berg T, Rappold G, Niesler B. First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol Genet 2008; 17: 2967-2977.
  • 4Zhou Q, Souba WW, Croce CM, Verne GN. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. Gut 2010; 59: 775-784.
  • 5熊青,徐龙.血清microRNAs在胃肠道疾病中的意义[J].世界华人消化杂志,2012,20(22):2043-2049. 被引量:7
  • 6Brase JC, Wuttig D, Kuner R, Sültmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010; 9: 306.
  • 7Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A. Serum microRNAs are promising novel biomarkers. PLoS One 2008; 3: e3148.
  • 8Shih KK, Levine DA. Exosomal microRNAs step into the biomarker arena. Gynecol Oncol 2008; 110: 1-2.
  • 9Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, Dai J, Hu Z, Zhou X, Chen L, Zhang Y, Li Y, Qiu H, Xing J, Liang Z, Ren B, Yang C, Zen K, Zhang CY. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 2010; 56: 1871-1879.
  • 10Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, Deng T, Liu H, Yin J, Wang S, Zen K, Ba Y, Zhang CY. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47: 784-791.

二级参考文献23

  • 1袁耀宗,许斌,莫剑忠,王吉耀,李兆申.马来酸曲美布汀治疗肠易激综合征的疗效和安全性研究[J].胃肠病学,2005,10(3):143-147. 被引量:107
  • 2杨欣艳,李世荣.微生态制剂在肠易激综合征治疗中的作用[J].中华医学杂志,2005,85(39):2802-2804. 被引量:16
  • 3Saito YA, Schoenfeld, Locke GRI 3rd. The epidemiology of irritable bowel syndrome in North America: a systemic review. Am J Gastroenterol, 2002, 97 : 1910-1915.
  • 4Xiong LS, Chen MH, Chen HX, et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmarcol Ther, 2004, 19 : 1217-1224.
  • 5Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology, 2002, 123: 2108-2131.
  • 6Devaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut, 2002, 51(Suppl 1): i67-i71.
  • 7Drossman DA, Ringel Y, Vogt BA, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gasroenterology, 2003, 124:754-761.
  • 8Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut, 2004, 53:1096-1101.
  • 9Longstreth GF, Thompson WG, Chey WD. Functional bowel disorders// Drossman DA. Rome Ⅲ : the functional gastrointertinal disorders. 2006:487-555.
  • 10Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther, 1997, 11:553-559.

共引文献436

同被引文献56

  • 1张海燕,吴萍,李延青,吴明波,张葆,吕亚丽.肠易激综合征患者的免疫学机制探讨[J].胃肠病学和肝病学杂志,2006,15(3):285-287. 被引量:17
  • 2吴萍,张海燕,张葆,鹿博,吴明波,吕亚丽.肠易激综合征患者细胞因子的变化及其临床意义[J].中国医师杂志,2006,8(10):1406-1407. 被引量:7
  • 3Malanchi I, Santamaria Martinez A, Susanto E, el al. In *eractions between cancer stem cells and their niche gov ern metastatic colonization[J ]. Nature, 2011,481 ( 7379 ): 85 -89.
  • 4Baek D, Vill6n J ,Shin C, et al. The impact of microRNAs on protein output[J]. Nature,2008,455(7209) :64-71.
  • 5Bartel DP. MicroRNAs: target recognition and regulatory functions[J]. Cell,2009,136(2) :215 -33.
  • 6Calin GA, Ferracin M, Cimmino A, et al. A MieroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia [J]. N Engl J Med, 2005, 353(17):1793-1801.
  • 7Selbach M, Schwanhiusser B, Thierfelder N, et al. Wide- spread changes in protein synthesis induced by microR- NAs[J]. Nature,2008,455(7209) :58-63.
  • 8Capodanno A, Boldrini L, Proietti A, et al. Let-7g and miR-21 expression in non-small cell lung cancer: Correla- tion with clinicopathological and molecular features[J]. Int J Onco1,2013,43(3) :765 774.
  • 9Takahashi Y, Forrest AR, Maeno E, et al. MiR-107 and MiR-185 can induce cell cyclc arrest in human non small cell lung cancer cell lines[J]. PLoS One. 2009, 4 (8): e6677.
  • 10Johnson SM,Grosshans H ,Shingara J ,et al. RAS is regu- lated by the let-7 microRNA family[J]. Cell, 2005,120 (5) :635-647.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部